IL22 and arthritic joint disease: The differential IL‐17:IL‐22 ratios (0.49 and 0.21 in the PBS‐ and ES‐62–treated groups, respectively, postchallenge; 0.26 and 0.31, respectively, prechallenge) and the ES‐62 sensitivity observed in the 2 groups further supported the idea that resetting of the IL‐17/IL‐22 balance in the joint correlates with ES‐62–mediated protection and perhaps suggests that additional/alternative inflammatory parameters contributed to the pathogenesis in mice that developed arthritis prior to challenge.